Imaging in HF-PEF with Cardiovascular Magnetic Resonance

Current Cardiovascular Imaging Reports

Volumn 8, Issue 3, 2015, Pages

  Hinojar, Rocio ^a   Fernández Golfín, Covadonga ^a   Zamorano, Jose Luis ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cardiac magnetic resonance; Diastolic dysfunction; Heart failure; Preserved ejection fraction

Indexed keywords

GADOLINIUM;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; EDEMA; FABRY DISEASE; HEART AMYLOIDOSIS; HEART ATRIUM FUNCTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INFLAMMATION; MITRAL VALVE; PERICARDIAL DISEASE; RELAXATION TIME; REVIEW;

EID: 84923834495     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-015-9321-5     Document Type: Review

References (68)

1. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.
2. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–55.
3. Puntmann VO, Nagel E, Hughes AD, Gebker R, Gaddum N, Chowienczyk P, et al. Gender-specific differences in myocardial deformation and aortic stiffness at rest and dobutamine stress. Hypertension. 2012;59(3):712–8.
4. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(20):2539–50. This consensus statement provides a strategy on ‘How to diagnose and how to exclude HFPEF’ based on the positive and negative predictive value of successive examinations, respectively.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.
6. Hinojar R, Botnar R, Kaski JC, Prasad S, Nagel E, Puntmann VO. Individualized cardiovascular risk assessment by cardiovascular magnetic resonance. Futur Cardiol. 2014;10(2):273–89.
7. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol. 2009;53:1475–87.
8. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108(1):54–9.
9. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26(15):1461–74.
10. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.
11. Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(7):1016–22.
12. Fattori R, Biagini E, Lorenzini M, Buttazzi K, Lovato L, Rapezzi C. Significance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Am J Cardiol. 2010;105:1592–6.
13. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009;54:242–9.
14. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875–87.
15. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014;130(6):484–95.
16. Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4):475–84. This study demonstrates that T1 mapping provides indexes with high diagnostic accuracy for the discrimination of normal and diffusely diseased myocardium.
17. Hinojar R, Goodman B, Villa A, Arroyo-Úcar E, Dabir D, Schaeffter T, et al. T1 mapping in discrimination between hypertrophic and hypertensive cardiomyopathy. J Cardiovasc Magn Reson. 2014;16 Suppl 1:O61.
18. Hinojar R, Goodman B, Villa A, Dabir D, Arroyo-Úcar E, Jackson T, et al. Native T1 values in discrimination of subclinical profibrotic phenotype in relatives of patients with hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2014;16 Suppl 1:241.
19. Moon JC, Sachdev B, Elkington AG. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24:2151–5.
20. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4(6):592–601.
21. Yousef Z, Elliott PM, Cecchi F, Escoubet B, Linhart A, Monserrat L, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J. 2013;34(11):802–8.
22. Kristen AV, Perz JB, Schonland SO, Hegenbart U, Schnabel PA, Kristen JH, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007;9:617–24.
23. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111(2):186–93.
24. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3(2):155–64.
25. Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Störk S, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(6):1066–72.
26. Klein AL, Abbara S, Agler DA, Appleton CP, Asher CR, Hoit B, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2013;26(9):965–1012.e15. Indepth recommendation on the management of pericardial diseases, in which multimodality imaging is an integral part of modern strategies.
27. Mirelis JG, Garcia-Alvarez A, Fernandez-Friera L, Sawit S, Hinojar R, Fuster V, et al. Respiratory ventricular area changes measured with real-time cardiac magnetic resonance: a new, accurate, and reproducible approach for the diagnosis of pericardial constriction. Int J Cardiol. 2013;166(1):267–71.
28. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–84.
29. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961–8.
30. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
31. Soldo SJ, Norris SL, Gober JR, et al. MRI-derived ventricular volume curves for the assessment of left ventricular function. Magn Reson Imaging. 1994;12:711–7.
32. Graca B, Ferreira MJ, Donato P, Castelo-Branco M, Caseiro-Alves F. Cardiovascular magnetic resonance imaging assessment of diastolic dysfunction in a population without heart disease: a gender-based study. Eur Radiol. 2014;24:52–9.
33. Hartiala JJ, Mostbeck GH, Foster E, Fujita N, Dulce MC, Chazouilleres AF, et al. Velocity-encoded cine MRI in the evaluation of left ventricular diastolic function: measurement of mitral valve and pulmonary vein flow velocities and flow volume across the mitral valve. Am Heart J. 1993;125:1054–66.
34. Bowman AW, Frihauf PA, Kovacs SJ. Time-varying effective mitral valve area: prediction and validation using cardiac MRI and Doppler echocardiography in normal subjects. Am J Physiol Heart Circ Physiol. 2004;287:H1650–7.
35. Fyrenius A, Wigstrom L, Bolger AF, Ebbers T, Ohman KP, Karlsson M, et al. Pitfalls in Doppler evaluation of diastolic function: insights from 3-dimensional magnetic resonance imaging. J Am Soc Echocardiogr. 1999;12:817–26.
36. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:165–93. Extensive overview of available echocardiographic techniques for diastolic function testing and recommended criteria for classifying the grade of dysfunction.
37. Rathi VK, Doyle M, Yamrozik J, et al. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: a practical approach. J Cardiovasc Magn Reson. 2008;10:36.
38. Bollache E, Redheuil A, Clément-Guinaudeau S, Defrance C, Perdrix L, Ladouceur M, et al. Automated left ventricular diastolic function evaluation from phase-contrast cardiovascular magnetic resonance and comparison with Doppler echocardiography. J Cardiovasc Magn Reson. 2010;12:63.
39. Brandts A, Bertini M, van Dijk EJ, Delgado V, Marsan NA, van der Geest RJ, et al. Left ventricular diastolic function assessment from three-dimensional three-directional velocity-encoded MRI with retrospective valve tracking. Magn Reson Imaging. 2011;33(2):312–9. Three-directional velocity-encoding is compared with conventional one-directional velocity-encoded MRI for assessing LV diastolic function. The clinical value of these techniques for classifying diastolic dysfunction is compared with echocardiography.
40. Joseph A, Kowallick JT, Merboldt KD, Voit D, Schaetz S, Zhang S, Sohns JM, Lotz J, Frahm J. Real-time flow MRI of the aorta at a resolution of 40 msec. J Magn Reson Imaging 2013.
41. Westenberg JJ. CMR for assessment of diastolic function. Curr Cardiovasc Imaging Rep. 2011;4(2):149–58.
42. Krishnamurthy R, Pednekar A, Cheong B, Muthupillai R. High temporal resolution SSFP cine MRI for estimation of left ventricular diastolic parameters. J Magn Reson Imaging. 2010;31:872–80.
43. Garot J, Bluemke DA, Osman NF, Rochitte CE, McVeigh ER, Zerhouni EA, et al. Fast determination of regional myocardial strain fields from tagged cardiac images using harmonic phase MRI. Circulation. 2000;101:981–8.
44. Castillo E, Osman NF, Rosen BD, El-Shehaby I, Pan L, Jerosch-Herold M, et al. Quantitative assessment of regional myocardial function with MR-tagging in a multi-center study: interobserver and intraobserver agreement of fast strain analysis with harmonic phase (HARP) MRI. J Cardiovasc Magn Reson. 2005;7:783–91.
45. Donekal S, Ambale-Venkatesh B, Berkowitz S, Wu CO, Choi EY, Fernandes V, et al. Inter-study reproducibility of cardiovascular magnetic resonance tagging. J Cardiovasc Magn Reson. 2013;15:37.
46. Edvardsen T, Rosen BD, Pan L, Jerosch-Herold M, Lai S, Hundley WG, et al. Regional diastolic dysfunction in individuals with left ventricular hypertrophy measured by tagged magnetic resonance imaging—the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2006;151(1):109–14.
47. Ennis DB, Epstein FH, Kellman P, Fananapazir L, McVeigh ER, Arai AE. Assessment of regional systolic and diastolic dysfunction in familial hypertrophic cardiomyopathy using MR tagging. Magn Reson Med. 2003;50(3):638–42.
48. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol. 2003;42:1199–205.
49. Pritchett AM, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol. 2005;45:87–92.
50. Douglas PS. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol. 2003;42:1206–7.
51. Sievers B, Kirchberg S, Addo M, et al. Assessment of left atrial volumes in sinus rhythm and atrial fibrillation using the biplane area-length method and cardiovascular magnetic resonance imaging with TrueFISP. J Cardiovasc Magn Reson. 2007;9:673–9.
52. Hudsmith LE, Petersen SE, Francis JM, et al. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:775–82.
53. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, et al. Left atrial minimum volume and reservoir function as correlates of left ventricular diastolic function: impact of left ventricular systolic function. Heart. 2012;98:813–20.
54. Posina K, McLaughlin J, Rhee P, Li L, Cheng J, Schapiro W, et al. Relationship of phasic left atrial volume and emptying function to left ventricular filling pressure: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2013;15:99. This study evaluates the relationship between left atrial volume and emptying fraction with invasive measures of left ventricular end diastolic pressure.
55. Kaminski M, Steel K, Jerosch-Herold M, Khin M, Tsang S, Hauser T, et al. Strong cardiovascular prognostic implication of quantitative left atrial contractile function assessed by cardiac magnetic resonance imaging in patients with chronic hypertension. J Cardiovasc Magn Reson. 2011;13:42.
56. Hor KN, Gottliebson WM, Carson C, Wash E, Cnota J, Fleck R, et al. Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. JACC Cardiovasc Imaging. 2010;3:144–51.
57. Morton G, Schuster A, Jogiya R, Kutty S, Beerbaum P, Nagel E. Inter-study reproducibility of cardiovascular magnetic resonance myocardial feature tracking. J Cardiovasc Magn Reson. 2012;14:43.
58. Okayama S, Nakano T, Uemura S, Fujimoto S, Somekawa S, Watanabe M, et al. Evaluation of left ventricular diastolic function by fractional area change using cine cardiovascular magnetic resonance: a feasibility study. J Cardiovasc Magn Reson. 2013;15:87.
59. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52(19):1574–80.
60. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138–44.
61. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99(13):932–7.
62. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888–95.
63. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71. The authors suggest a systemic proinflammatory state induced by comorbidities as the cause of myocardial structural and functional alterations in HFPEF.
64. VO Puntmann, PC Taylor, A Barr, B Schnackenburg, C Jahnke, I Paetsch. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology 49(3):528–35.
65. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.
66. Puntmann VO, D’Cruz D, Smith Z, Pastor A, Choong P, Voigt T, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013;6(2):295–301.
67. Su MY, Lin LY, Tseng YH, Chang CC, Wu CK, Lin JL, et al. CMR verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014;7(10):991–7. This study investigates the association between the degree of diffuse myocardial fibrosis and the severity of impaired diastolic function in patients with HF.
68. Puntmann VO, Arroyo Ucar E, Hinojar Baydes R, Ngah NB, Kuo YS, Dabir D, et al. Aortic stiffness and interstitial myocardial fibrosis by native T1 are independently associated with left ventricular remodeling in patients with dilated cardiomyopathy. Hypertension. 2014;64(4):762–8. This study provides a novel concept by showing that increase in aortic stiffness relates to myocardial remodeling via accumulation of myocardial fibrosis in the presence of cardiovascular disease.